GSA Capital Partners’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $291K | Sell |
62,322
-76,413
| -55% | -$357K | 0.02% | 1271 |
|
|
2025
Q1 | $762K | Buy |
138,735
+88,892
| +178% | +$488K | 0.07% | 516 |
|
|
2024
Q4 | $169K | Buy |
49,843
+22,493
| +82% | +$76.3K | 0.01% | 1453 |
|
|
2024
Q3 | $78K | Sell |
27,350
-578,313
| -95% | -$1.65M | 0.01% | 1506 |
|
|
2024
Q2 | $1.36M | Buy |
605,663
+593,952
| +5,072% | +$1.34M | 0.1% | 314 |
|
|
2024
Q1 | $26K | Sell |
11,711
-404,556
| -97% | -$898K | ﹤0.01% | 1550 |
|
|
2023
Q4 | $978K | Buy |
416,267
+35,036
| +9% | +$82.3K | 0.08% | 409 |
|
|
2023
Q3 | $709K | Buy |
381,231
+348,016
| +1,048% | +$647K | 0.06% | 585 |
|
|
2023
Q2 | $87K | Sell |
33,215
-282,810
| -89% | -$741K | 0.01% | 1385 |
|
|
2023
Q1 | $515K | Buy |
+316,025
| New | +$515K | 0.05% | 694 |
|
|
2022
Q4 | – | Sell |
-50,094
| Closed | -$78K | – | 1946 |
|
|
2022
Q3 | $78K | Buy |
50,094
+5,458
| +12% | +$8.5K | 0.01% | 1389 |
|
|
2022
Q2 | $69K | Sell |
44,636
-72,671
| -62% | -$112K | 0.01% | 1262 |
|
|
2022
Q1 | $300K | Buy |
117,307
+6,035
| +5% | +$15.4K | 0.04% | 893 |
|
|
2021
Q4 | $326K | Buy |
+111,272
| New | +$326K | 0.04% | 876 |
|
|
2021
Q3 | – | Sell |
-173,318
| Closed | -$705K | – | 1821 |
|
|
2021
Q2 | $705K | Buy |
173,318
+85,121
| +97% | +$346K | 0.08% | 416 |
|
|
2021
Q1 | $398K | Buy |
+88,197
| New | +$398K | 0.07% | 475 |
|
|
2020
Q2 | – | Sell |
-69,800
| Closed | -$136K | – | 1168 |
|
|
2020
Q1 | $136K | Buy |
69,800
+22,222
| +47% | +$43.3K | 0.03% | 843 |
|
|
2019
Q4 | $335K | Buy |
+47,578
| New | +$335K | 0.04% | 940 |
|